Why am I working today?

[Anonymous]

If they decide not to promote Nuvigil, why would any of CNS be kept?

Cephalon Drops Nuvigil Patent Suit Against Teva

By Ben James

Law360, New York (May 11, 2011) -- Cephalon Inc. dropped its patent infringement suit in Delaware against Teva Pharmaceuticals USA Inc. on Wednesday, resolving one of several cases in a multidistrict litigation over the narcolepsy drug Nuvigil.

U.S. District Judge Gregory M. Sleet signed off on a stipulation and order dismissing the case, which had been brought by Cephalon and Cephalon France in December 2009.

Cephalon's original complaint asserted three patents, but the plaintiffs dropped their claims with respect to two of those in May 2010. The dismissal follows Teva amending the certification...

 

[Anonymous]

I am also with Teva and can only say that our sales forces for our branded divisions are lean. That's not to say there won't be some overlap in areas, but for a buyout, I don't see it getting any better than this for two sales forces coming together. Cephalon has entire divisions that Teva doesn't, so those people would likely be kept. And these two companies together make a strong pipeline for multiple therapeutic areas that good reps can be shuffled around to.

This is just my opinion. I have no hard data from anyone in our company on this subject, but I wouldn't paint a doom and gloom picture just yet. Wait to see what happens as the buyout deal is final.

 

[Anonymous]

August 18th Provigil will go generic and sold to company from Russia